The Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Eli Lilly's significant price increase for Mounjaro in the UK signals a broader repricing trend in the weight-loss market. This shift, driven by U.S. policy pressures, could alter the competitive landscape as pharmaceutical companies adjust international prices to balance global revenue streams.
What You Need to Know
This collection focuses on companies across the weight-loss value chain, from established market leaders to emerging biotechs developing alternative treatments. Price sensitivity among patients and healthcare systems could drive demand toward more cost-effective options in this high-growth sector.
Why These Stocks
These companies were handpicked by professional analysts to capture the event-driven opportunity created by pricing shifts in the blockbuster GLP-1 therapy market. They represent potential beneficiaries as the market seeks alternatives to higher-priced treatments.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+542.52%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 542.52% over the next year.
Stocks Rated Buy by Analysts
15 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Price Wars Create Winners
When blockbuster drugs get more expensive, competitors often benefit as patients and providers seek affordable alternatives. This pricing shift could reshape the entire weight-loss market landscape.
Global Policy Ripple Effects
U.S. drug pricing policies are now directly impacting international markets, creating new investment opportunities. This precedent could trigger similar moves across the pharmaceutical industry.
Booming Market Opportunity
The weight-loss drug market is experiencing explosive growth, and pricing disruptions often accelerate competition. These companies are positioned to capture market share in this high-demand sector.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Navigating Inflation: Companies With Pricing Power
A surprise surge in wholesale prices signals renewed inflationary pressures across the U.S. economy. This theme focuses on companies with strong pricing power, which allows them to protect profitability by passing increased costs on to consumers.
Healthcare's Cybersecurity Imperative
The massive cyberattack on UnitedHealth's subsidiary has exposed critical vulnerabilities within the national healthcare system. This event is accelerating the demand for advanced cybersecurity solutions, creating a significant growth opportunity for firms that specialize in protecting sensitive medical data and infrastructure.
Digital Guardians: Investing In Online Child Safety
Following a report on Meta's AI policies, U.S. senators are demanding an investigation, highlighting a critical need for enhanced online child safety. This regulatory pressure could boost companies that provide digital safety, content moderation, and identity verification services for online platforms.
Frequently Asked Questions
Everything you need to know about the product and billing.